Alaunos Therapeutics, Inc.TCRTEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Deep AnalysisCompare

Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.